Management of Mild‑to‑Moderate Auricular Irritant Dermatitis

Potency Classification and Comparative Efficacy

Over‑the‑counter hydrocortisone (0.5 %–1 %) is a low‑potency (Class VII) topical corticosteroid, whereas 0.1 % triamcinolone acetonide is a mid‑potency (Class IV–V) agent, indicating greater anti‑inflammatory strength for the latter. 1

Mid‑potency corticosteroids such as triamcinolone carry a risk of hypothalamic‑pituitary‑adrenal axis suppression and possible growth interference in children, especially when used in very potent or potent categories. 2
Very potent and potent corticosteroid preparations should be limited to short courses to minimize systemic and local adverse effects. 2

Topical corticosteroids should generally not be applied more than twice daily; newer formulations may be effective with once‑daily dosing. 2
For moderate‑to‑severe inflammatory dermatoses, continuous use beyond 8 weeks is not recommended; an 8‑week maximum is considered a sensible limit for short‑term therapy. 4

Initiate therapy for mild auricular irritant dermatitis with over‑the‑counter hydrocortisone 1 % applied twice daily for 7–14 days. 1
Escalate to 0.1 % triamcinolone acetonide if:
Limit triamcinolone use on thin facial or auricular skin to a maximum of 2–4 weeks, then step down to hydrocortisone for maintenance therapy. 4

Steroid phobia can lead to undertreatment and poor disease control; clinicians should address patient or caregiver concerns about corticosteroid safety. 2
Prolonged application of mid‑potency steroids on the thin skin of the ear and face increases the risk of atrophic changes; duration should be strictly limited. 4
Failure to clearly explain the benefits, risks, and rationale for step‑up/step‑down regimens may result in non‑adherence and suboptimal outcomes. 2

Topical calcineurin inhibitors (tacrolimus 0.03 %–0.1 % or pimecrolimus 1 %) provide a safe anti‑inflammatory option for patients where corticosteroid side effects are a concern, especially for long‑term or facial use. 6